Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 24, 2026, 10:25 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 313–336 of 1,263 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Copd Clear all
Completed Not applicable Interventional

Rehabilitation for Patients With COPD

NCT03287440
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
COPD Wellness, Health Advocate
Behavioral
Lead sponsor
University of California, San Francisco
Other
Eligibility
40 Years to 95 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jun 3, 2022 · Synced Oct 24, 2026, 10:25 PM EDT
Completed Phase 4 Interventional Results available

Tiotropium (18mcg) in Chronic Obstructive Pulmonary Disease (COPD) Patients With a Respiratory Infection

NCT01483625
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
tiotropium, Placebo
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
40 Years and older
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
27
States / cities
Tucson, Arizona • Riverside, California • San Diego, California + 24 more
Source: ClinicalTrials.gov public record
Updated Jun 9, 2014 · Synced Oct 24, 2026, 10:25 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

The Leaky Lung Test

NCT02306473
View directory record Official record
Conditions
Asthma, Allergy, Reactive Airway Disease, Lung Diseases, Obstructive
Interventions
Mannitol
Drug
Lead sponsor
University of Rochester
Other
Eligibility
18 Years to 80 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Jan 4, 2018 · Synced Oct 24, 2026, 10:25 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

COPD Patient-Powered Research Network

NCT02803242
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disorder, Chronic Obstructive Lung Disease, Emphysema, Chronic Bronchitis
Interventions
Patient Reported Outcomes
Other
Lead sponsor
COPD Foundation
Other
Eligibility
18 Years and older
Enrollment
75,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2030
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Mar 10, 2022 · Synced Oct 24, 2026, 10:25 PM EDT
Completed Phase 2 Interventional Results available

Comparison of Two Treatment Regimens to Reduce PA Infection in Children With Cystic Fibrosis

NCT00097773
View directory record Official record
Conditions
Cystic Fibrosis, Pulmonary Disease, Chronic Obstructive
Interventions
Tobramycin solution for inhalation (TOBI), Oral placebo, Oral ciprofloxacin
Drug
Lead sponsor
Seattle Children's Hospital
Other
Eligibility
1 Year to 12 Years
Enrollment
304 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
54
States / cities
Birmingham, Alabama • Los Angeles, California • Oakland, California + 49 more
Source: ClinicalTrials.gov public record
Updated Feb 28, 2014 · Synced Oct 24, 2026, 10:25 PM EDT
Completed Phase 3 Interventional Results available

A Phase IIIb Study to Evaluate the Efficacy of Umeclidinium/Vilanterol (UMEC/VI) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

NCT02152605
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
UMEC/VI, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years and older
Enrollment
498 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
11
States / cities
Phoenix, Arizona • Upland, California • Clearwater, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Nov 9, 2017 · Synced Oct 24, 2026, 10:25 PM EDT
Terminated Not applicable Interventional

Evaluating Genes in Sputum to Measure Drug Response in COPD

NCT00233051
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease (COPD), Emphysema, Chronic Bronchitis
Interventions
Salmeterol or Salmeterol/Fluticasone
Drug
Lead sponsor
National Jewish Health
Other
Eligibility
40 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Mar 29, 2017 · Synced Oct 24, 2026, 10:25 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Indacaterol Plus Tiotropium Versus Tiotropium Alone in Patients With Chronic Obstructive Pulmonary Disease

NCT00877383
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease (COPD)
Interventions
Indacaterol 150 μg, Tiotropium 18 μg, Placebo to indacaterol
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
40 Years and older
Enrollment
1,142 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
116
States / cities
Anniston, Alabama • Birmingham, Alabama • Jasper, Alabama + 102 more
Source: ClinicalTrials.gov public record
Updated Aug 25, 2011 · Synced Oct 24, 2026, 10:25 PM EDT
Recruiting Phase 2 Interventional

To Evaluate the Effect of EXPD-101/FXS7553 Compared With Placebo in Patients With COPD Over 52 Weeks of Treatment

NCT07684820
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease (COPD)
Interventions
EXPD-101/FXS7553 Dose 1, EXPD-101/FXS7553 Dose 2, Placebo
Drug
Lead sponsor
Expedition Therapeutics, Inc
Industry
Eligibility
40 Years to 85 Years
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
22
States / cities
Phoenix, Arizona • Northridge, California • Aurora, Colorado + 19 more
Source: ClinicalTrials.gov public record
Updated Sep 30, 2026 · Synced Oct 24, 2026, 10:25 PM EDT
Terminated No phase listed Observational Accepts healthy volunteers

Detection and Characterization of Pulmonary Disease by Transthoracic Doppler (TTD)

NCT01618721
View directory record Official record
Conditions
Lung Disease, Chronic Obstructive, Lung Disease, Interstitial
Interventions
Not listed
Lead sponsor
Echosense Ltd.
Industry
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2011
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 24, 2014 · Synced Oct 24, 2026, 10:25 PM EDT
Completed No phase listed Observational Results available

A Study Using US Medical and Pharmacy Claim Records to Compare the Resource Use, Cost, and Outcomes of People With COPD Who Take Either Tiotropium + Olodaterol or Fluticasone + Umeclidinium + Vilanterol

NCT05127304
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Trelegy Ellipta, Stiolto Respimat, Furoate/Umeclidinium/Vilanterol, Tiotropium Bromide/Olodaterol
Device · Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
40 Years and older
Enrollment
11,316 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Eden Prairie, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 13, 2023 · Synced Oct 24, 2026, 10:25 PM EDT
Completed Phase 3 Interventional Results available

A Study to Compare the Efficacy and Safety of Umeclidinium/Vilanterol and Fluticasone Propionate/Salmeterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

NCT01817764
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Umeclidinium/vilanterol, Fluticasone propionate/salmeterol, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years and older
Enrollment
707 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
9
States / cities
Jasper, Alabama • Phoenix, Arizona • San Diego, California + 6 more
Source: ClinicalTrials.gov public record
Updated Nov 8, 2017 · Synced Oct 24, 2026, 10:25 PM EDT
Completed Not applicable Interventional Results available

Increasing Adherence to Pulmonary Rehabilitation After COPD Related Hospitalizations (Pilot Study)

NCT03865329
View directory record Official record
Conditions
COPD Exacerbation
Interventions
Intervention- Home-based Pulmonary Rehabilitation
Behavioral
Lead sponsor
Mayo Clinic
Other
Eligibility
40 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 10, 2020 · Synced Oct 24, 2026, 10:25 PM EDT
Terminated Not applicable Interventional

Comparative Trial of Home-Based Palliative Care

NCT03694431
View directory record Official record
Conditions
Cancer, Chronic Obstructive Pulmonary Disease, Heart Failure, Dementia, End Stage Liver Disease, End Stage Renal Disease, Neuromuscular Diseases
Interventions
Tech-supported HBPC, Standard HBPC
Other
Lead sponsor
Kaiser Permanente
Other
Eligibility
18 Years and older
Enrollment
3,999 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
2
States / cities
Pasadena, California • Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Feb 20, 2020 · Synced Oct 24, 2026, 10:25 PM EDT
Terminated Phase 3 Interventional

Tiotropium/Salmeterol Inhalation Powder (Spiriva Handihaler and Salmeterol Polyethylene (PE) Capsule) in Chronic Obstructive Pulmonary Disease (COPD)

NCT00662740
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Tiotropium/Salmeterol QD, Placebo, Salmeterol, Tiotropium/Salmeterol QD+ Salmeterol, Tiotropium (Spiriva®)
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
40 Years and older
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
20
States / cities
Boulder, Colorado • Wheat Ridge, Colorado • Winter Park, Florida + 16 more
Source: ClinicalTrials.gov public record
Updated Aug 23, 2023 · Synced Oct 24, 2026, 10:25 PM EDT
Completed Not applicable Interventional Results available

INtervention Study In overweiGHT Patients With COPD

NCT02634268
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive, Obesity, Weight Loss, Life Style, Overweight
Interventions
Lifestyle Intervention
Behavioral
Lead sponsor
Seattle Institute for Biomedical and Clinical Research
Other
Eligibility
40 Years and older
Enrollment
684 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
39
States / cities
Birmingham, Alabama • Tucson, Arizona • Los Angeles, California + 32 more
Source: ClinicalTrials.gov public record
Updated Apr 7, 2022 · Synced Oct 24, 2026, 10:25 PM EDT
Completed Phase 2 Interventional Results available

A Study To Evaluate The Efficacy, Safety, Pharmacokinetics, And Pharmacodynamic Effects Of GDC-6599 In Patients With Chronic Cough

NCT05660850
View directory record Official record
Conditions
Chronic Refractory Cough (CRC) With Non-atopic Asthma, CRC With Atopic Asthma, Unexplained Chronic Cough, CRC With Chronic Obstructive Pulmonary Disease, CRC With Chronic Obstructive Pulmonary Disease With Chronic Bronchitis
Interventions
GDC-6599, GDC-6599-matching placebo, Mannitol
Drug · Other · Diagnostic Test
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
8
States / cities
Los Angeles, California • Northridge, California • Coral Gables, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Dec 16, 2025 · Synced Oct 24, 2026, 10:25 PM EDT
Not listed Phase 1 Interventional

Comparison of Bronchodilator Response From Three Different Aerosol Delivery Methods in Patients With COPD Using Hyperpolarized Xe 129 MRI Ventilation Imaging

NCT06271408
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Albuterol Sulfate, 2.5 Mg/3 mL (0.083%) Inhalation Solution, Vibrating Mesh Nebulizer, Metered Dose Inhaler, Jet Nebulizer
Drug · Device
Lead sponsor
Polarean, Inc.
Industry
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Feb 21, 2024 · Synced Oct 24, 2026, 10:25 PM EDT
Terminated No phase listed Observational

The Relationship Between GOLD Risk Group and Clinical Outcomes in a Community-based COPD Cohort

NCT02838108
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease (COPD), Emphysema, Chronic Bronchitis
Interventions
Not listed
Lead sponsor
Duke University
Other
Eligibility
40 Years and older
Enrollment
452 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Kannapolis, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 29, 2019 · Synced Oct 24, 2026, 10:25 PM EDT
Completed Phase 1 Interventional

Acute Bronchodilator Effect of Inhaled Albuterol Sulfate and Ipratropium Bromide in Patients With Stable COPD

NCT03480997
View directory record Official record
Conditions
COPD
Interventions
Albuterol Sulfate and Ipratropium Bromide, Albuterol Sulfate
Combination Product
Lead sponsor
Pneuma Respiratory, Inc
Industry
Eligibility
40 Years to 80 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Hickory, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 29, 2018 · Synced Oct 24, 2026, 10:25 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Benralizumab in Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) With Exacerbation History

NCT02155660
View directory record Official record
Conditions
Moderate to Very Severe Chronic Obstructive Pulmonary Disease
Interventions
Benralizumab Arm A, Benralizumab Arm B, Benralizumab Arm C, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
40 Years to 85 Years
Enrollment
2,255 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
151
States / cities
Birmingham, Alabama • Gulf Shores, Alabama • Montgomery, Alabama + 127 more
Source: ClinicalTrials.gov public record
Updated Jun 26, 2019 · Synced Oct 24, 2026, 10:25 PM EDT
Completed No phase listed Observational Accepts healthy volunteers Results available

Longitudinal Follow up to Assess Biomarkers Predictive of Emphysema Progression in Patients With COPD (Chronic Obstructive Pulmonary Disease)

NCT02719184
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive, Pulmonary Emphysema
Interventions
Not listed
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
40 Years to 60 Years
Enrollment
463 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2021
U.S. locations
11
States / cities
Birmingham, Alabama • San Diego, California • Torrance, California + 8 more
Source: ClinicalTrials.gov public record
Updated Aug 16, 2024 · Synced Oct 24, 2026, 10:25 PM EDT
Completed Phase 2 Interventional Results available

Investigation of Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Efficacy of Oral Danirixin in Symptomatic COPD Subjects With Mild to Moderate Airflow Limitation at Risk for Exacerbations

NCT02130193
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Danirixin, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years to 70 Years
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
6
States / cities
Birmingham, Alabama • Denver, Colorado • Iowa City, Iowa + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 24, 2026, 10:25 PM EDT